Kicking KRAS to tackle lung cancer

KRAS is one of the most commonly mutated oncogenes in lung cancer but has long been considered undruggable. With the recent FDA approval of sotorasib, supported by positive phase II trial data now published in The New England Journal of Medicine, this is no longer the case.

Detalles Bibliográficos
Autor principal: Abbott, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053182/
https://www.ncbi.nlm.nih.gov/pubmed/35602221
http://dx.doi.org/10.1038/s43856-021-00017-z
Descripción
Sumario:KRAS is one of the most commonly mutated oncogenes in lung cancer but has long been considered undruggable. With the recent FDA approval of sotorasib, supported by positive phase II trial data now published in The New England Journal of Medicine, this is no longer the case.

Ejemplares similares